US 11,938,167 B2
Pharmaceutical compositions and methods targeting Wnt pathway proteins
Joshua Rabbani, New York, NY (US); Xiaofeng Li, Farmington, CT (US); and James J. Donegan, Amesbury, MA (US)
Assigned to ENZO BIOCHEM, INC., Farmingdale, NY (US); and ENZO THERAPEUTICS, INC., New York, NY (US)
Filed by Enzo Biochem, Inc., New York, NY (US); and Enzo Therapeutics, Inc., Farmingdale, NY (US)
Filed on Oct. 5, 2021, as Appl. No. 17/493,896.
Application 17/493,896 is a continuation of application No. 16/396,896, filed on Apr. 29, 2019, granted, now 11,167,011.
Application 16/396,896 is a continuation of application No. 15/195,017, filed on Jun. 28, 2016, granted, now 10,328,120, issued on Jun. 25, 2019.
Application 15/195,017 is a continuation of application No. 13/170,634, filed on Jun. 28, 2011, granted, now 9,403,882, issued on Jul. 13, 2016.
Application 13/170,634 is a continuation in part of application No. 13/088,059, filed on Apr. 15, 2011, granted, now 9,493,541, issued on Oct. 26, 2016.
Application 13/088,059 is a continuation in part of application No. 12/802,447, filed on Jun. 7, 2010, granted, now 9,617,323, issued on Mar. 22, 2017.
Prior Publication US 2022/0023383 A1, Jan. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 38/08 (2019.01); A61K 38/10 (2006.01); C07K 14/47 (2006.01); C07K 14/51 (2006.01); C07K 14/705 (2006.01); C07K 14/71 (2006.01)
CPC A61K 38/1709 (2013.01) [A61K 38/08 (2013.01); A61K 38/10 (2013.01); C07K 14/47 (2013.01); C07K 14/51 (2013.01); C07K 14/705 (2013.01); C07K 14/71 (2013.01)] 10 Claims
 
1. A method of enhancing a Wnt signaling pathway, comprising contacting an LRP/6 receptor in the Wnt signaling pathway with a synthetic peptide less than 50 amino acids in length, the peptide comprising a sequence of human sclerostin (SEQ ID NO: 30) that includes ELGEYPEPPPELENNK (SEQ ID NO: 5) or ELGEYPEPPPELE (SEQ ID NO: 9).